Investing in (LSE: GSK ) in April 2026 presents a transition from a historically "unloved" stock to a growth-oriented specialty biopharma player. Since demerging its consumer health arm (Haleon) in 2022, GSK has significantly outpaced the FTSE 100. GSK plc (GSK) GBX 1,831.50 9.86% since Jan 2, 2026 As of Apr 27, 19:52 GMT+3 • Disclaimer Apr 27, 2026 Open2,018.00 Mkt cap$109.86B USD 52-wk high2,282.00 High2,023.00 P/E ratio14.49 52-wk low1,288.60 Low1,999.00 Div yield3.28% Financial Snapshot (April 2026) Market Price : ~2,012 GBX (up nearly 60% in 12 months).
: Trades at ~10.3x to 14.5x 2026 adjusted earnings. buy gsk shares
: Strong market position with Shingrix (shingles) and Arexvy (RSV). Investing in (LSE: GSK ) in April 2026
: Five major product approvals were achieved in 2025; two more expected in 2026 for bepirovirsen and tebipenem . : Trades at ~10